Browse studies

Find your next paid study

930 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

Estimated

~$10 – $8,750

Mersana TherapeuticsNCT05514717

Phase 1

A Phase I Study of DFP-14927 in Patients With Advanced Solid Tumors

This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid t…

Solid TumorCancer

Estimated

~$10 – $8,750

Delta-Fly Pharma, Inc.NCT03943004

Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study

The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cance…

NeoplasmsNeoplasm MalignantAdvanced Cancer+2 more

Estimated

~$10 – $1,125

Advanced Integrative Medical Science InstituteNCT04495790

Phase 1

A Phase 1/1b, Multicenter, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Pharmacodynamics, and Pharmacokinetics of ODC-IL2 Administered Via Intravenous Infusion in Adult Patients With Advanced or Metastatic Solid Tumors

This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 …

Advanced Solid TumorsMetastatic Solid Tumors

Estimated

~$10 – $8,750

Trutino Biosciences Inc.NCT06770764

Phase 1

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senapari…

Solid TumorAdvanced Solid Tumor

Estimated

~$10 – $8,750

Impact Therapeutics, Inc.NCT05269316

Phase 2

A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to preve…

Breast CancerBreast Cancer Stage IBreast Cancer Stage II+34 more

Estimated

~$10 – $6,250

Phase 1

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and effica…

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more

Estimated

~$10 – $8,750

Tanabe Pharma America, Inc.

Phase 1

A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Pha…

A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors

The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with …

Lung Cancer (NSCLC)Prostate CancerEsophageal Cancer+1 more

Estimated

~$10 – $8,750

Phrontline BiopharmaNCT07181473

Observational

Physiologic MR Imaging in Distinguishing Benign From Malignant Salivary Gland Tumors

The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous saliv…

Salivary Gland Tumor

Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT04452162

Phase 1

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence: A Multi-Institutional Study

Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and complete treatment in remission. High-risk patients however, freq…

Solid Tumor

Estimated

~$10 – $6,250

Miller Children's & Women's Hospital Long BeachNCT02446431

Phase 1

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with doc…

Advanced Solid Tumors

Estimated

~$10 – $8,750

Vividion Therapeutics, Inc.NCT05954312